Charles River Laboratories International, Inc. (CRL)
| Market Cap | 12.59B +52.6% |
| Revenue (ttm) | 4.00B -0.7% |
| Net Income | -238.46M |
| EPS | -4.88 |
| Shares Out | 47.74M |
| PE Ratio | n/a |
| Forward PE | 21.49 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 118,144 |
| Open | 261.53 |
| Previous Close | 265.51 |
| Day's Range | 261.14 - 266.67 |
| 52-Week Range | 144.26 - 268.00 |
| Beta | 1.38 |
| Analysts | Buy |
| Price Target | 267.71 (+1.53%) |
| Earnings Date | Aug 5, 2026 |
About CRL
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, ins... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for CRL stock is "Buy." The 12-month stock price target is $267.71, which is an increase of 1.53% from the latest price.
News
Charles River price target raised to $300 from $260 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Charles River (CRL) to $300 from $260 and keeps an Overweight rating on the shares.
Charles River price target raised to $291 from $255 at Baird
Baird raised the firm’s price target on Charles River (CRL) to $291 from $255 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results.
Charles River price target raised to $300 from $260 at Deutsche Bank
Deutsche Bank analyst Justin Bowers raised the firm’s price target on Charles River (CRL) to $300 from $260 and keeps a Buy rating on the shares.
Charles River price target raised to $282 from $215 at RBC Capital
RBC Capital raised the firm’s price target on Charles River (CRL) to $282 from $215 and keeps an Outperform rating on the shares.
JPMorgan upgrades Charles River to Overweight following strong Q2
JPMorgan upgraded Charles River (CRL) to Overweight from Neutral with a price target of $310, up from $180. The company delivered strong Q2 results while raising 2026 guidance on the…
Charles River upgraded to Overweight from Neutral at JPMorgan
JPMorgan upgraded Charles River (CRL) to Overweight from Neutral with a price target of $310, up from $180.
Charles River price target raised to $300 from $220 at Barclays
Barclays raised the firm’s price target on Charles River (CRL) to $300 from $220 and keeps an Overweight rating on the shares.
Charles River price target raised to $300 from $260 at Evercore ISI
Evercore ISI raised the firm’s price target on Charles River (CRL) to $300 from $260 and keeps an Outperform rating on the shares. The company’s first quarter of organic revenue…
Charles River Laboratories International Earnings Call Transcript: Q2 2026
Second quarter results exceeded expectations, with organic revenue growth, margin expansion, and strong DSA bookings. Full-year guidance was raised for revenue, EPS, and free cash flow, supported by portfolio refinement and robust biopharma demand.
Charles River Laboratories International Earnings release: Q2 2026
Charles River Laboratories International released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Charles River Laboratories International Slides: Q2 2026
Charles River Laboratories International has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Charles River Laboratories International Quarterly report: Q2 2026
Charles River Laboratories International has published its Q2 2026 quarterly earnings report on August 5, 2026.
Charles River lifts profit forecast on improving biotech demand
Contract drug developer Charles River Laboratories on Wednesday raised its annual profit forecast after quarterly results beat estimates, as it banked on stronger demand for its drug discovery and d...
Charles River Laboratories Announces Second-Quarter 2026 Results
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Second-Quarter 2026 Financial Results.
Charles River downgraded to Hold from Outperform at CLSA
CLSA analyst Michael Luo downgraded Charles River (CRL) to Hold from Outperform with an unchanged price target of $219. The firm believes the current share price already reflects a gradual…
Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call.
Charles River announces collaboration with Arovella Therapeutics
Charles River (CRL) Laboratories International announced a collaboration with Arovella Therapeutics. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T c...
Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology...
Charles River price target raised to $230 from $192 at Mizuho
Mizuho raised the firm’s price target on Charles River (CRL) to $230 from $192 and keeps a Neutral rating on the shares. The firm adjusted targets in the healthcare facilities…
Charles River price target raised to $260 from $220 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Charles River (CRL) to $260 from $220 and keeps an Overweight rating on the shares. The firm is updating its model ahead…
Citi adds ‘upside 90-day catalyst watch’ on Charles River
Citi analyst Patrick Donnelly is adding an “upside 90-day catalyst watch” on Charles River (CRL) while keeping a Buy rating and $265 price target on the shares. The firm believes…
Did Charles River Laboratories International, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Charles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing Expertise
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River Laboratories International, Inc. (NYSE: CRL) announced a collaboration with Lilly TuneLab, a collaborative AI/ML drug discovery pl...
Charles River Laboratories International Transcript: Jefferies Global Healthcare Conference 2026
Leadership transition drives a new strategy focused on simplification, margin improvement, and growth, with significant divestitures and cost savings underway. Investments in AI and NAMs support efficiency and animal reduction, while demand stabilizes and manufacturing margins are set to recover above 30%.